Text

Artesunat-Amodiakuin dan Klorokuin untuk Pengobatan Malaria Vivaks di Puskesmas Kopeta, Maumere, Nusa Tenggara Timur, 2007

---

Indonesia as a malaria endemic country is recommended to use Artemisinin-based Combination Therapy (ACT) for P. vivax malaria. Confirmation of Chloroquine resistant and ACT efficacy for P. vivax need to be investigated for supporting malaria treatment policy. Papua and East Nusa Tenggara (NTT) contribute the main malaria cases in Indonesia.

To evaluate efficacy and safety of Artesunate Amodiaquine (AsAq) as an ACT programme compared to drug Klorokuin (Cq) as a conventional for vivax malaria at Public Health Care in NTT. This was a clinical study, prospective, efficacy and safety evaluation of AsAq compared to Cq for malaria P.vivax subject and followed by 28 days, based on WHO protocol 2003. Intention to treat (ITT) and per protocol (PP) was performed to compare AsAq and Cq efficacy. Safety was evaluated based on the incidance or severity of clinical symptoms by 28 days of follow up.

Total of 100 P. vivax monoinfection suitable with the inclusion/exclusion criteria was randomized treated with AsAq or Cq. The 28 days efficacy of AsAq and Cq was 93.7% (95%CI: 83.8 – 97.9) versus 56.4% (95%CI: 50.1 – 75.9) with Log Rank (Mantel Cox)

---

Ketersediaan

Informasi Detail

Judul Seri

-

No. Panggil

Media Litbangkes, 24 (4) : 161-168

Penerbit

Jakarta : Sekretariat Balitbangkes., 2014

Deskripsi Fisik

8p

Bahasa

ISBN/ISSN

0853-9987

Klasifikasi

-

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

-

Subjek

AMODIAQUINE
PLASMODIUM VIVAX

Info Detail Spesifik

-

Pernyataan Tanggungjawab

-

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar